{"disease":{"id":"metastatic-ovarian-cancer","name":"metastatic ovarian cancer"},"drugs":{"marketed":[{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"endocrine-therapy-1","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endocrine Therapy 1","generic_name":"endocrine-therapy-1","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Endocrine Therapy 1","quality_score":null,"revenue":null,"mechanism":"Endocrine Therapy 1"},{"drug_id":"endocrine-therapy-2","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endocrine Therapy 2","generic_name":"endocrine-therapy-2","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Endocrine Therapy 2","quality_score":null,"revenue":null,"mechanism":"Endocrine Therapy 2"},{"drug_id":"pf-06873600","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06873600","generic_name":"pf-06873600","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-06873600 tablet for oral dosing","quality_score":null,"revenue":null,"mechanism":"PF-06873600 tablet for oral dosing"}],"offLabel":[],"totalMarketed":1,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT01174121","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":332,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05796973","title":"Measuring Oncological Value of Exercise and Statin","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Tampere University Hospital","has_results":false},{"nct_id":"NCT03519178","title":"A Study of PF-06873600 in People With Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":155,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01768156","title":"Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Institut du Cancer de Montpellier - Val d'Aurelle","has_results":false},{"nct_id":"NCT04998760","title":"A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"Qi Zhou","has_results":false},{"nct_id":"NCT03294694","title":"Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":33,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03277482","title":"Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03412526","title":"Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Sheba Medical Center","has_results":false},{"nct_id":"NCT03242993","title":"[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"University of Lausanne Hospitals","has_results":false},{"nct_id":"NCT06533332","title":"A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"EtiraRx Australia Pty Ltd","has_results":false},{"nct_id":"NCT03287674","title":"TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Inge Marie Svane","has_results":true},{"nct_id":"NCT04611126","title":"T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Inge Marie Svane","has_results":true},{"nct_id":"NCT03634150","title":"Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Immune System Key Ltd","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}